Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03232424 · ClinicalTrials.gov registry record · Phase 1
NovoTTF-200A and Temozolomide Chemoradiation for Newly Diagnosed Glioblastoma
A Phase 1 study, sponsored by Hackensack Meridian Health.
- Completed
- Registry status
- Phase 1
- Development phase
- 12
- Enrollment target
NCT03232424 is a Phase 1 study that has completed, run by Hackensack Meridian Health. The registered enrollment target is 12 participants.
The verdict
NCT03232424, a Phase 1 study, has completed, sponsored by Hackensack Meridian Health.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 12 participants
- Enrollment target
Study Summary
This study is a prospective single arm trial designed to study the safety, feasibility and preliminary efficacy of a medical device, NovoTTF-200A used concomitantly with standard adjuvant treatment for newly diagnosed glioblastoma.
Interventions
- DRUG Temozolomide
- DEVICE NovoTTF-200A
- RADIATION 3D conformal or intensity modulated radiation therapy (IMRT)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12 participants |
| Start Date | 2017-07-26 |
| Est. Completion | 2022-12-07 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03232424
The ClinicalTrials.gov registry entry for NCT03232424 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 12 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Hackensack Meridian Health, which has 90 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Temozolomide is the first listed.
NCT03232424 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03232424 about?
NCT03232424 is a clinical study titled "NovoTTF-200A and Temozolomide Chemoradiation for Newly Diagnosed Glioblastoma". This study is a prospective single arm trial designed to study the safety, feasibility and preliminary efficacy of a medical device, NovoTTF-200A used concomitantly with standard adjuvant treatment for newly diagnosed glioblastoma.
What is the current status of trial NCT03232424?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 12 participants. The study started on 2017-07-26. Estimated completion is 2022-12-07.
What interventions are being tested in trial NCT03232424?
The interventions under investigation include: Temozolomide (DRUG), NovoTTF-200A (DEVICE), 3D conformal or intensity modulated radiation therapy (IMRT) (RADIATION).
Who is sponsoring clinical trial NCT03232424?
This trial is sponsored by Hackensack Meridian Health, which has 90 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.